Certara

Certara helps drug companies and researchers predict how new medicines will work. Its software and services guide drugs from early research to regulatory approval. Hospitals, regulators, and scientists use Certara to make drug development safer and faster.

Products and Services

• Biosimulation Software: Predicts how drugs behave in the body for researchers and regulators.
• Technology-Enabled Services (56% of 2025 revenue): Offers consulting and data analysis to support drug development and regulatory submissions.
• Scientific Informatics: Manages chemical and biological data for drug discovery teams.
• Data Standardization & Compliance: Ensures clinical trial data meets regulatory standards for approval.
• AI Platforms: Uses artificial intelligence to automate regulatory writing and analyze scientific data.

Growth and Expansion

• Acquired Chemaxon in 2024 to expand into drug discovery informatics.
• Acquired Formedix and Applied BioMath in 2023, adding clinical data automation and advanced modeling.
• Launched over 100 new software applications and upgrades in 2025, including AI-powered modules.
• Expanded operations to 28 countries by 2025, increasing international revenue share to 31%.
• Integrated AI across its product portfolio, including regulatory writing and biosimulation tools.

What Makes Certara Stand Out

Certara combines software, consulting, and AI to support drug development from start to finish. Its platforms are used by over 160,000 users and 20 global regulatory agencies. The company’s broad customer base and validated models help reduce risk in drug research.

Five Things You Need to Know

• Revenue was $418.8 million in 2025, up 9% from 2024.
• Software revenue grew 18% in 2025, reaching $183.3 million.
• International sales made up 31% of total revenue in 2025.
• Operating income was $21.0 million in 2025, reversing a loss in 2024.

Bottom Line

Certara has evolved through acquisitions, global expansion, and AI integration. Its mix of software and services supports a wide range of drug development needs.